Hims House

Jonathan Stern
  • 5.0 (8)
  • Investing
  • Semiweekly

Hims House is the ultimate podcast for Hims & Hers investors. Hosted by Jonathan Stern and Patrick Lester, Hims House breaks down all the key questions shaping $HIMS — from telehealth and pharma to GLP-1s, compounding, and the future of healthcare. New episodes every week. himshouse.substack.com

  1. 2d ago

    🚨 BPC-157 and five other peptides just got the green light: "It's going to be a knife fight"

    Thanks to our partners: Superpower - https://superpower.com CareValidate - https://carevalidate.com/himshouse Subscribe to Hims House: https://himshouse.com Follow us: https://x.com/himshouse https://x.com/jonathanrstern https://x.com/jefftangx In episode 86, Jonathan Stern talks with Jeff Tang, a Y Combinator founder who sold his longevity meal prep company to Bryan Johnson and now hosts Peptide Parties in SF and LA Jeff thinks Hims is right to let Superpower and Enhanced go first, since the biggest player has the most to lose. He expects the new ban on peptide blends (like the "Wolverine Stack") to be mostly ignored, and says anyone taking peptides should carry an EpiPen. Then we get into the 4 peptides Hims is not planning to sell at launch, and why peptide ads on Meta may stay in limbo until LegitScript updates its rules. We also cover TikTok's recent ban on peptide searches. 00:00 - Sponsors: Superpower + CareValidate 01:03 - 6 peptides cleared: "It's going to be a knife fight" 02:30 - Why Hims should be Apple: best, not first 03:47 - Why the ban on BPC-157 + TB-500 blends (Wolverine Stack) will be ignored 05:56 - Peptide parties 11:24 - The 4 peptides Hims left out 14:47 - Will Ro sit out peptides?! 👀 17:15 - Hims' rivals + telehealths that hit 9-figures 20:28 - LegitScript + Meta ads 28:42 - TikTok's ban on peptide searches 34:10 - Superpower pricing vs. the gray market 39:43 - Jeff's peptide stack: tirz, tesamorelin, and cerebrolysin (made from pig brains) 45:30 - Predictions: a MOTS-c hospitalization + state-by-state rules 49:57 - What will be the top peptide in 5 years? Disclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions.

    🚨 BPC-157 and five other peptides just got the green light: "It's going to be a knife fight"

  2. 6d ago

    Why Hims & Hers may be the most asymmetric opportunity in the entire stock market

    Thanks to our partners: Superpower - https://superpower.com CareValidate - https://carevalidate.com/himshouse Follow us: https://x.com/himshouse https://x.com/jonathanrstern https://x.com/TravisHoium https://youtube.com/@asymmetricinvesting https://asymmetric-investing.beehiiv.com In episode 85, Jonathan Stern talks with Travis Hoium, founder of Asymmetric Investing, who started buying Hims in spring 2024 and has never sold a share. Travis explains why he calls Hims "the modern pharma company," with the doctor and pharmacy in one place and insurance left out, and why he wants operating margins near zero while subscribers grow. He makes the case for kids as Hims' next category, starting with the refills parents already chase every few months. Then he takes on Jonathan's list of worries, from gross margin falling to 64% to Ro catching up. We close on peptides and what $HIMS could be worth 5 years from now. 00:00 - Sponsors: Superpower + CareValidate 02:11 - First bought in the teens in 2024, never sold a share 08:12 - Hims = "the modern pharma company" 13:26 - Travis pitches "Hims for Kids" 22:21 - Gross margin fell from 82% to 64%. Why he's not worried 26:06 - Shipping delays & surprise charges 30:45 - Ro has caught up to Hims in credit card data 33:17 - Hims slow AI / tech progress? 36:38 - Hims should sync with every device 40:49 - Why no drug company will pay for peptide research 44:22 - Could peptides add $1 billion in revenue next year? 52:07 - Why Hims refuses to take insurance, and Ro does 53:45 - Insider buying and selling 57:03 - Why Hims could go from 2x to 10x sales Disclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions.

    Why Hims & Hers may be the most asymmetric opportunity in the entire stock market

  3. Oct 20

    Why payment processors treat peptides as "riskier than gambling", per gray-market peptide CEO

    Thanks to our partners: Superpower - https://superpower.com CareValidate - https://carevalidate.com FDA warning letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026 In episode 84, Jonathan Stern talks with Zak David, founder of Peptide Partners, one of the largest research-peptide sellers in the US. This is Zak's first and only interview discussing Peptide Partners' FDA warning letter! We get into why payment processors consider research peptides riskier than gambling, what advice he'd give Hims, and whether the gray market will be even bigger in three years. Zak also responds to Martin Shkreli's claim that peptides are setting Western medicine back 70 years. 00:00 - Sponsors: Superpower + CareValidate 01:49 - How Zak found peptides 04:19 - 80% of vials now "fill-finished" in the US 06:15 - Just under 100K customers all-time 08:48 - Retatrutide is #1 12:33 - Zak's take on the FDA letter 20:25 - Peptides "riskier than gambling" to payment processors 25:01 - Why they now test more than 10 vials per batch 31:06 - All China today, India lab coming in December 31:04 - Peptide Partners' supply chain today 34:58 - American-made peptide potential pricing 40:48 - Grindr's $250 million deal 46:32 - TSA agent recognized his peptide vials 49:48 - Zak's advice to Hims & Andrew Dudum 52:22 - Why Shkreli is wrong about peptides Disclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions.

    Why payment processors treat peptides as "riskier than gambling", per gray-market peptide CEO

  4. Oct 15

    Are Peptides Coming By End Of Year?

    Thanks to our partners: Superpower - https://superpower.com CareValidate - https://carevalidate.com In episode 83, Jonathan Stern talks with Scott Brunner, CEO of the Alliance for Pharmacy Compounding, the trade group for more than 600 compounding businesses, about the WaPo report that the administration may let pharmacies sell certain peptides before a formal rule is finished. Brunner says he thinks an announcement is "highly likely" before EOY, and he wants conditions on it: ingredients only from FDA-registered wholesalers, a clearer warning to patients, and reports of serious side effects. 00:00 - Sponsors 01:22 - Peptides may be "imminent" 09:36 - The guardrails the Scott is advocating for 14:00 - RFK is driving this through 19:26 - Pharmacies may need 2-3 months to get ready 23:08 - Which peptides would be included? 25:57 - What about 503B facilities? 28:22 - How long formal rulemaking takes 30:45 - U.S. peptide API capacity will take time 32:56 - Future of the gray market 35:52 - The Empower warning letter and future of compounded GLP-1s 39:28 - Congressional bills Scott is watching Disclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions.

    Are Peptides Coming By End Of Year?

  5. Oct 8

    Brazil's 2nd-largest telehealth CEO on how Hims & Hers should enter Brazil 🇧🇷

    Thanks to our partner: Superpower - https://superpower.com In episode 82, Jonathan Stern talks with Abrahão Fecury, co-founder and CEO of Eles & Elas, a Brazilian telehealth company built on the Hims playbook and now at about R$4.5 million (~$1 million USD) in annual revenue, growing about +10% a month. Weight loss is about 70% of that (compounded tirzepatide) at a 54% gross margin, with hair loss and mental health smaller and more profitable. Fecury walks through cash-pay pharmacies, Meta and WhatsApp customer acquisition, and how ANVISA's summer ban on Voy changed the category. We close with a discussion about Hims & Hers - where he says, if Hims wants to expand into Brazil, it should "absolutely buy" a telehealth in Brazil (like Voy or Eles & Elas) vs building everything itself. 00:00 - Sponsor: Superpower 04:51 - Revenue of R$4.5 million (~$1 million USD) 10:25 - Margins of each category 13:35 - Brazil healthcare 101 16:43 - 1 in 4 adults in Brazil has obesity 19:22 - Meta Ads brings in 80% of customers 24:30 - Why ANVISA banned Voy, then reversed it on August 5 28:32 - Voy "more than 10x Eles & Elas' revenue" 30:57 - Generic semaglutide margin is only 5-10% 34:26 - Lilly suing in Brazil too 35:30 - Paraguay shenanigans 40:38 - Hims should buy a telehealth to expand into Brazil 48:34 - Other countries in LatAm Disclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions.

    Brazil's 2nd-largest telehealth CEO on how Hims & Hers should enter Brazil 🇧🇷

  6. Oct 1

    Finnrick CEO on gray market peptides, fake bodega vials, and China's manufacturing prowess

    Thanks to our partner:Superpower - https://superpower.com

    Finnrick CEO on gray market peptides, fake bodega vials, and China's manufacturing prowess

  7. Sep 16

    OpenLoop CEO: the peptide gray market is 2-3x bigger than analyst estimates, likely $6-8 billion

    Thanks to our partner:Superpower - https://superpower.com In episode 80 of Hims House, Jonathan Stern talks with Dr. Jon Lensing, co-founder and CEO of OpenLoop, the white-label company that runs telehealth behind the scenes for other brands. Lensing started OpenLoop out of the University of Iowa's medical school and says the platform will see more than 8 million patients this year and treat more than a million a month, across 400-plus brands from telehealth companies to grocery stores, dating apps, and gyms. He said he thinks GLP-1s will become a default medication the way statins did for cholesterol: he expects 80% of people over 30 could be on them by 2035, and he thinks Andrew Dudum's path to $40-$50 a month cash-pay is directionally right, maybe lower. On peptides he thinks some could be legal to compound before year-end, but not all at once. And he sizes today's gray market at $6 to $8 billion. 00:00 - Sponsor: Superpower 01:37 - The Shopify of virtual healthcare 04:32 - OpenLoop serving 8M patients this year 05:33 - MEDVi 07:08 - OpenLoop's January data breach 08:13 - Consumerism in healthcare 10:38 - 80% of people over 30 will be on GLP-1s 16:22 - Peptides likely this year, but not all at once 18:46 - Ready to launch peptides the day FDA allows 21:17 - Peptide API from FDA green-listed vendors 22:51 - Peptide gray market is $6 to $8 billion 27:01 - AI data moats Disclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions.

    OpenLoop CEO: the peptide gray market is 2-3x bigger than analyst estimates, likely $6-8 billion

  8. Sep 3

    HIMS stock token hit $132 on Robinhood over the weekend due to ... $BONER coin?! 😳

    Thanks to our partner:Superpower - https://superpower.com 🚨 WARNING: This is not a typical Hims House podcast! I wanted to do this interview because what happened on Robinhood Chain this weekend directly affected $HIMS -- and I think Hims investors should at minimum understand what happened. Jonathan Stern talks with Eric, an Ethereum OG and the world's largest $BONER holder, and Yoni, co-founder of Long.xyz, about BONER — a memecoin on Robinhood Chain paired with the $HIMS stock token. BONER reached roughly 12,000 holders in five days and helped make Hims a top-15 Robinhood stock token. Then, with the NYSE closed and limited Hims tokens available on-chain, $HIMS briefly traded at $132 versus a $28.75 NYSE close. Token supply jumped from roughly 20,000 to 80,000 in 72 hours. Eric and Yoni both stress that BONER is highly speculative and could go to zero. But Eric's longer-term thesis is that every major tokenized stock could eventually develop its own memecoin community. 00:00 - Sponsor: Superpower 01:27 - Why should Hims investors care? 03:35 - 12K Boner holders in five days 06:00 - Why buy Boner instead of the stock token 14:31 - 99% of meme coins go to zero 19:00 - Open pairing: Boner-Hims 22:27 - $132 on chain vs $28.75 on the NYSE 26:44 - Could this trigger a short squeeze? 34:06 - Has anyone at Hims called? 36:25 - Every major stock gets a meme coin community Disclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions.

    HIMS stock token hit $132 on Robinhood over the weekend due to ... $BONER coin?! 😳
See All (86)

Ratings & Reviews

5
out of 5
8 Ratings

About

Hims House is the ultimate podcast for Hims & Hers investors. Hosted by Jonathan Stern and Patrick Lester, Hims House breaks down all the key questions shaping $HIMS — from telehealth and pharma to GLP-1s, compounding, and the future of healthcare. New episodes every week. himshouse.substack.com

Information

  • Creator
    Jonathan Stern
  • Years Active
    2024 - 2026
  • Episodes
    86
  • Rating
    Clean
  • Copyright
    © Jonathan Stern
  • Show Website
    Hims House

You Might Also Like